notion
develop
countri
must
wait
develop
world
make
advanc
scienc
technolog
later
import
great
cost
challeng
previous
argu
develop
countri
har
human
genet
variat
benefit
popul
economi
base
empir
studi
largescal
popul
genotyp
project
mexico
india
thailand
describ
resourc
adopt
improv
public
health
creat
knowledgebas
economi
signific
addit
benefit
build
capac
scientif
research
intern
advanc
technolog
whatev
sourc
natur
review
genet
volum
june
perspect
collin
et
al
describ
futur
genom
research
hous
human
genom
project
foundat
question
rais
live
hous
lucki
industri
economi
peopl
abl
find
room
matter
come
use
genom
inform
develop
therapeut
grow
industri
countri
develop
world
howev
advanc
genom
perceiv
reach
critic
question
countri
would
invest
genom
research
face
press
health
need
poverti
infecti
diseas
lack
basic
infrastructur
addit
high
cost
associ
genom
research
inadequaci
exist
regulatori
intellectu
properti
regim
seen
signific
obstacl
argu
develop
countri
one
least
afford
wast
limit
health
resourc
ineffect
diagnost
therapi
immedi
health
applic
result
invest
genom
scienc
develop
countri
global
attain
sequenc
genom
microorgan
virus
sever
acut
respiratori
syndrom
sar
coronaviru
influenza
viru
infecti
diseas
major
caus
morbid
mortal
develop
countri
rate
noncommunic
diseas
also
increas
current
onethird
death
world
caus
cardiovascular
diseas
nearli
occur
develop
nation
year
number
new
cancer
case
increas
stagger
develop
countri
oppos
develop
countri
want
assess
resourc
develop
countri
alreadi
possess
improv
public
health
chose
focu
case
studi
largescal
genotyp
initi
human
popul
stand
address
infecti
diseas
host
respons
well
chronic
diseas
better
understand
correl
genotyp
phenotyp
invest
field
identifi
nich
area
within
within
area
local
interest
build
life
sciencesbas
capac
around
knowledg
develop
countri
might
contribut
improv
local
health
also
potenti
stimul
econom
develop
least
approach
help
understand
diseas
suscept
drug
respons
local
popul
increas
realiz
scienc
technolog
vital
human
develop
life
scienc
particularli
relev
develop
countri
break
cycl
depend
emerg
economi
develop
countri
begin
build
infrastructur
local
innov
captur
valu
scientif
research
concept
genom
sovereignti
describ
articl
link
wish
three
countri
describ
mexico
india
thailand
captur
valu
invest
largescal
genotyp
project
crucial
outcom
invest
project
relat
lifesci
technolog
acceler
capac
build
scientif
research
abil
intern
new
technolog
whether
spawn
local
import
despit
percept
benefit
genom
unattain
outsid
industri
world
largescal
genotyp
effort
explor
human
genom
variat
initi
sever
emerg
market
discuss
result
crosscomparison
three
case
studi
genotyp
initi
take
place
mexico
india
thailand
use
previous
describ
method
box
conduct
indepth
interview
develop
case
studi
mexican
nation
genom
medicin
institut
inmegen
box
indian
genom
variat
databas
consortium
igvdb
consortium
box
two
smaller
initi
thailand
thailand
snp
discoveri
project
pharmacogenom
project
thailand
centr
excel
life
scienc
tcel
box
explor
motiv
undertak
largescal
genotyp
initi
adopt
genom
medicin
countri
mechan
three
countri
envis
implement
develop
genom
medicin
appropri
circumst
potenti
ethic
legal
social
cultur
issu
arisen
might
aris
result
defin
genom
medicin
health
applic
deriv
genom
approach
research
manifest
amongst
other
boutiqu
person
medicin
popul
subpopul
level
pharmacogenom
theragnost
littl
data
base
empir
studi
describ
emerg
knowledg
human
genom
variat
practic
appli
improv
health
develop
world
find
provid
snapshot
interest
emerg
develop
economi
interest
evolut
genom
studi
particularli
intersect
public
health
potenti
sourc
econom
activ
respect
find
relev
privat
sector
industri
develop
countri
intern
organ
interest
scienc
technolog
use
achiev
acceler
health
secur
human
develop
gener
crosscomparison
analysi
case
gener
roadmap
help
reader
better
understand
way
three
countri
har
human
genom
variat
studi
roadmap
made
sever
common
theme
emerg
data
repres
key
factor
contribut
establish
potenti
futur
success
initi
studi
includ
polit
institut
leadership
local
health
benefit
genom
sovereignti
aspir
creat
knowledgebas
economi
polit
three
countri
govern
leadership
polit
support
andor
govern
legisl
crucial
establish
genotyp
project
discuss
thailand
tcel
overse
thai
pharmacogenom
project
establish
royal
decre
king
thailand
june
similarli
mexico
inmegen
first
depart
mexican
nation
institut
health
mnih
legisl
support
polit
parti
congress
thu
provid
strong
messag
genom
medicin
prioriti
mexican
peopl
subsequ
inmegen
receiv
initi
invest
us
million
mexican
govern
ministri
health
india
pledg
million
toward
research
medic
genom
recent
indian
govern
nation
biotechnolog
develop
strategi
thai
govern
nation
biotechnolog
polici
framework
identifi
genom
medicin
invest
opportun
accordingli
igvdb
consortium
receiv
public
fund
genotyp
initi
feder
govern
council
scientif
industri
research
undoubtedli
polit
instrument
initi
develop
stage
initi
enabl
access
necessari
public
fund
nevertheless
given
genom
medicin
initi
still
infanc
object
criteria
measur
success
yet
agre
upon
importantli
develop
countri
critic
suggest
promis
human
genom
project
overhyp
fail
deliv
potenti
context
definit
success
probabl
pose
challeng
initi
mexico
thailand
india
seek
continu
polit
support
healthi
sceptic
call
narrow
understand
potenti
genom
critic
inde
valid
encount
sceptic
voic
exampl
key
inform
worri
inmegen
superflu
expens
maintain
howev
consid
genom
wide
especi
includ
capac
improv
public
health
pictur
differ
exampl
much
better
abl
track
sar
genom
sequenc
diseas
surfac
year
ago
nevertheless
genotyp
initi
discuss
qualit
case
studi
method
use
research
case
studi
follow
genotyp
initi
select
three
reason
first
knowledg
initi
advanc
respect
plan
implement
second
countri
initi
hous
give
good
region
represent
third
access
key
inform
facilit
exist
contact
individu
involv
initi
collect
data
june
januari
perform
indepth
facetofac
teleconfer
call
semistructur
interview
key
inform
repres
scientist
manag
mexican
nation
institut
genom
medicin
inmegen
indian
genom
variat
databas
igvdb
consortium
thai
snp
initi
nation
center
genet
engin
biotechnolog
thailand
biotec
thai
centr
excel
life
scienc
tcel
well
key
inform
divers
background
media
nongovernment
organ
regulatori
agenc
ministri
health
expert
area
genom
pharmacogenet
andor
ethic
develop
develop
countri
also
collect
data
document
publicli
avail
materi
relev
studi
question
interview
last
approxim
one
hour
audiotap
transcrib
data
analys
sever
phase
theme
categori
identifi
analys
interview
transcript
gener
open
code
analysi
word
repetit
key
term
key
word
next
phase
data
analysi
consist
axial
code
data
build
connect
within
theme
categori
final
phase
core
concept
identifi
use
select
code
ensur
authent
studi
member
research
group
crossvalid
code
studi
approv
committe
use
human
subject
univers
toronto
canada
interviewe
provid
written
consent
mexican
nation
institut
genom
medicin
inmegen
one
twelv
nation
institut
health
mexico
creat
aim
develop
nation
platform
genom
medicin
focus
nation
health
problem
base
genom
structur
mexican
popul
receiv
initi
invest
us
million
mexican
govern
mexico
popul
consid
mestizo
result
dynam
admixtur
ethnic
group
spaniard
lesser
extent
african
within
last
year
inmegen
genotyp
mestizo
differ
region
mexico
analys
snp
inform
trigger
seri
diseaserel
genom
studi
mexico
use
improv
health
care
mexican
popul
like
use
latin
american
countri
similar
popul
profil
inmegen
first
step
focus
gener
mexican
hapmap
order
facilit
next
phase
research
concentr
relat
genom
inform
mexican
popul
signific
caus
morbid
mortal
mexico
includ
macular
degener
diabet
mellitu
hypertens
obes
cancer
infecti
diseas
cardiovascular
diseas
need
anticip
sceptic
establish
strateg
plan
outlin
criteria
use
measur
success
key
inform
point
inmegen
tcel
leadership
establish
commun
strategi
engag
public
matter
genom
instanc
effort
engag
young
mexican
public
issu
genom
medicin
inmegen
develop
comic
book
seri
entitl
la
medicina
el
genoma
humano
describ
human
genom
potenti
applic
ethic
legal
social
issu
aris
human
genom
addit
institut
promot
understand
mexican
hapmap
project
radio
appear
public
gener
public
similarli
tcel
conjunct
local
scientist
prepar
book
pharmacogenom
layman
releas
june
initi
publicli
fund
henc
depend
upon
public
support
invest
public
engag
programm
help
rais
level
understand
public
possibl
increas
likelihood
public
support
howev
mexico
thailand
key
inform
told
us
local
critic
consid
genom
public
engag
activ
propaganda
although
public
understand
ensur
public
demand
genom
product
servic
encourag
physician
implement
genom
medicin
practic
genom
institut
strike
balanc
public
relat
activ
proper
public
engag
activ
avoid
hype
despit
concern
increas
public
understand
genom
ensur
public
realist
expect
benefit
associ
genom
medicin
well
length
time
take
reap
benefit
institut
leadership
three
countri
also
led
intern
collabor
exampl
inmegen
engag
sever
strateg
collabor
industri
countri
includ
intern
headquart
spain
pharmacogenet
everi
nation
initi
pgeni
translat
genom
research
institut
tgen
john
hopkin
univers
broad
institut
public
popul
project
genom
collabor
enabl
inmegen
particip
research
polici
decis
intern
level
frequent
led
industri
countri
indic
invest
genom
medicin
provid
inmegen
opportun
particip
global
economi
likewis
research
lead
genotyp
initi
india
thailand
collabor
human
genom
organis
hugo
panasian
snp
consortium
intern
genotyp
project
focus
anthropolog
human
migrat
box
consortium
requir
scientif
group
differ
geopolit
environ
vari
level
scientif
infrastructur
work
togeth
toward
common
goal
accord
key
inform
sever
crucial
factor
contribut
success
includ
leadership
equal
partnership
good
intent
stewardship
consensu
result
hugo
panasian
snp
consortium
gener
goodwil
member
countri
turn
might
act
foundat
futur
panasian
collabor
studi
focu
upon
health
oppos
anthropolog
northsouth
southsouth
collabor
valuabl
leverag
infrastructur
avail
host
countri
benefit
less
welldevelop
countri
enabl
particip
equal
contributor
genom
increas
likelihood
reap
benefit
previou
work
shown
polit
institut
leadership
necessari
promot
success
biotechnolog
sector
develop
countri
case
studi
provid
evid
develop
countri
leverag
two
characterist
order
coordin
necessari
polici
public
requir
establish
genotyp
initi
eventu
adopt
genom
medicin
invest
genotyp
project
provid
countri
necessari
tool
better
understand
drug
respons
diseas
mechan
diseas
suscept
popul
howev
translat
evidencebas
popul
allel
frequenc
target
health
intervent
local
popul
seen
challeng
global
mexico
challeng
address
integr
inmegen
within
mexican
ministri
health
facilit
effect
translat
genom
find
public
health
applic
specif
key
inform
thought
result
inmegen
studi
could
inform
local
health
decis
make
exampl
focus
health
promot
campaign
mexican
subpopul
might
higher
risk
certain
chronic
diseas
inmegen
work
plan
support
model
public
health
genom
report
genom
medicin
potenti
reduc
mexican
healthcar
cost
relat
diabet
manag
ref
found
featur
inmegen
uniqu
develop
world
accord
one
key
inform
largescal
genotyp
project
capac
build
associ
alreadi
acceler
abil
countri
deal
public
health
problem
india
tool
genom
analysi
exampl
use
genotyp
polio
japanes
enceph
virus
enabl
public
health
offici
research
identifi
evolut
spread
differ
strain
thu
public
health
offici
abl
track
manag
infecti
diseas
outbreak
effect
initi
indian
genom
variat
databas
igvdb
consortium
collabor
network
institut
genom
integr
biolog
igib
centr
cellular
molecular
biolog
ccmb
indian
institut
chemic
biolog
iicb
central
drug
research
institut
cdri
industri
toxicolog
research
centr
itrc
institut
microbi
technolog
imtech
aim
consortium
construct
public
dnavari
databas
sampl
unrel
indian
subpopul
select
basi
geograph
local
linguist
categori
aim
research
diseas
predisposit
advers
drug
reaction
popul
migrat
ultim
goal
improv
local
global
health
linguist
categori
includ
tibetoburman
dravidian
indoeuropean
austroasiat
northern
southern
eastern
western
central
northeastern
india
thu
far
phase
analysi
carri
valid
ongo
report
novel
snp
locat
within
diseas
gene
thought
preval
indian
global
popul
although
igvdb
consortium
provid
data
use
academ
commun
research
conduct
igvdb
consortium
result
discoveri
andor
potenti
commerci
opportun
protect
intellectu
properti
need
licens
downstream
applic
like
emerg
basic
research
conduct
india
exampl
research
igvdb
consortium
recent
demonstr
associ
haplotyp
locu
encod
receptor
respons
salbutamol
asthma
patient
indian
popul
other
found
possibl
link
tardiv
dyskinesia
specif
polymorph
locat
within
catecholomethyltransferas
comt
gene
data
studi
could
lead
improv
diagnost
treatment
patient
india
contrast
inmegen
igvdb
consortium
tcel
pharmacogenom
project
thai
snp
discoveri
project
incorpor
within
respect
health
ministri
consequ
although
key
inform
emphas
initi
would
use
better
understand
biolog
determin
diseas
address
local
preval
health
concern
reduc
healthcar
cost
improv
use
therapeut
reduc
advers
drug
reaction
yet
clear
quickli
knowledg
adopt
public
health
intervent
pose
particular
challeng
context
thailand
health
system
offer
univers
health
coverag
govern
decid
genom
medicin
rank
term
resourc
alloc
achiev
local
health
benefit
genom
medicin
lofti
challeng
one
mani
key
inform
describ
key
motiv
maintain
achiev
long
term
health
applic
develop
initi
widescal
adopt
genom
medicin
deliveri
product
servic
vari
depend
countri
local
health
care
deliveri
system
instanc
unlik
mexico
india
thailand
implement
univers
health
care
could
serv
driver
adopt
genom
medicin
could
turn
promot
public
health
save
one
applic
two
thai
key
inform
cite
amen
public
health
intervent
screen
patient
human
immunodefici
viru
hiv
suscept
nevirapineinduc
skin
rash
nevirapin
antiretrovir
treatment
told
commonli
use
thailand
nevertheless
number
concern
rais
interviewe
regard
capac
within
rural
commun
develop
countri
take
technolog
concern
rang
aspect
regard
public
physician
understand
abil
deliv
servic
concern
rais
issu
develop
countri
benefit
new
technolog
need
address
appropri
govern
method
order
ensur
equit
deliveri
access
genom
sovereignti
unit
nation
educ
scientif
cultur
organ
unesco
declar
human
genom
heritag
human
record
session
gener
confer
volum
resolut
critic
suggest
stanc
could
result
biocoloni
genet
piraci
human
sampl
develop
countri
resourc
carri
research
sever
key
inform
mexico
maintain
uniqu
pattern
variat
might
exist
subpopul
implic
develop
genom
diagnost
genom
medicin
equival
sovereign
resourc
similarli
india
histori
lobbi
protect
indian
genom
foreign
exploit
respons
export
human
sampl
foreign
research
often
fail
acknowledg
indian
collabor
particip
consist
idea
uniqu
pattern
genom
variat
sovereign
resourc
protect
foreign
prospector
mexico
recent
enact
amend
mexico
gener
health
law
aim
protect
nation
genom
sovereignti
mexican
india
although
specif
legisl
concern
genom
sovereignti
countri
made
effort
prevent
wholesal
export
human
biolog
materi
without
prior
arrang
govern
guidelin
exchang
human
biolog
materi
biomed
research
purpos
last
revis
novemb
contrast
thailand
concept
genom
sovereignti
appear
explicitli
key
inform
interview
although
recognit
need
protect
thai
dna
sampl
clear
regul
legisl
note
although
institut
guidelin
within
univers
hospit
central
nation
legisl
export
human
dna
sampl
howev
thai
research
express
concern
guidelin
andor
legisl
pertain
genom
sovereignti
might
imped
intern
collabor
partnership
abil
implement
genom
sovereignti
legisl
protect
resourc
foreign
exploit
seem
key
countri
ensur
leverag
genom
variat
data
encourag
local
innov
particip
equal
partner
global
knowledgebas
economi
thai
snp
discoveri
project
collabor
mahidol
univers
faculti
medicin
ramathibodi
hospit
oracl
co
ltd
thailand
nation
center
genet
engin
biotechnolog
biotec
thailand
centr
nation
de
genotypag
cng
franc
snp
databas
contain
allel
frequenc
linkag
disequilibrium
ld
block
pattern
gene
identifi
human
genom
regulatori
region
thai
popul
french
japanes
african
databas
also
contain
inform
genom
sequenc
genom
structur
primer
sequenc
function
genom
inform
inform
databas
use
identifi
diseaseassoci
gene
candid
gene
approach
systemat
genom
screen
pharmacogenom
research
also
form
thai
contribut
human
genom
organis
hugo
panasian
snp
consortium
thailand
centr
excel
life
scienc
tcel
pharmacogenom
project
perform
snp
genotyp
gene
involv
drug
respons
exampl
collect
sampl
five
pharmacogenom
project
human
immunodefici
viru
hiv
pharmacogenom
project
nevirapineinduc
skin
rash
see
main
text
drug
allergi
allopurinol
carbamazepin
pharmacogenom
childhood
acut
lymphoblast
leukaemia
pharmacogenom
oncolog
chemotherapi
use
fluorouracil
pharmacogenom
thalassaemia
addit
tcel
collabor
riken
institut
japan
collect
sampl
patient
posttraumat
stress
disord
attempt
understand
genom
contribut
syndrom
diseas
area
investig
tcel
pharmacogenom
project
includ
diabet
cardiovascular
diseas
rheumatoid
arthriti
hivaid
lupu
childhood
leukaemia
dihydropyrimidin
dehydrogenas
dpd
defici
knowledgebas
economi
key
inform
studi
indic
stimul
economi
innov
desir
outcom
seem
particularli
relev
key
inform
inmegen
stress
outcom
major
motiv
creation
genom
medicin
platform
saw
invest
genom
medicin
potenti
entri
point
mexico
global
knowledgebas
economi
although
intellectu
properti
protect
guarante
develop
commerci
product
mani
still
suggest
health
biotechnolog
intellectu
properti
protect
remain
vital
factor
toward
establish
privat
sector
commerci
product
develop
countri
earli
exampl
shantha
biotechn
privat
spinout
compani
osmania
univers
hyderabad
india
leverag
patent
innov
manufactur
process
pichia
pastori
express
system
produc
recombin
hepat
b
vaccin
result
subsequ
abl
drive
cost
hepat
b
vaccin
within
india
although
exampl
specif
health
biotechnolog
model
also
applic
genom
medicin
given
critic
inadequaci
intellectu
properti
protect
system
develop
countri
decid
focu
initi
chose
approach
challeng
mechan
intellectu
properti
protect
exist
mexico
india
thailand
mexico
thailand
inmegen
tcel
activ
engag
specif
intellectu
properti
commerci
activ
hope
offset
gener
opinion
countri
tradit
weak
patent
cultur
especi
among
academ
hospit
research
howev
establish
intellectu
properti
protect
system
seem
involv
differ
strategi
found
inmegen
member
igvdb
consortium
tcel
pharmacogenom
project
develop
explor
model
facilit
translat
earli
stage
research
commerci
product
inmegen
comprehens
plan
intellectu
properti
protect
enter
collabor
relationship
mexican
institut
intellectu
properti
impi
share
expertis
current
impi
inmegen
negoti
million
grant
would
enabl
maintain
inhous
intellectu
properti
offic
inmegen
could
provid
mexican
research
infrastructur
expertis
need
acquir
patent
research
inmegen
also
intend
use
impi
grant
kickstart
inhous
busi
incub
key
factor
technolog
innov
offer
support
consult
servic
busi
plan
commerci
market
oper
inform
technolog
key
inform
inmegen
argu
institut
integr
within
mnih
system
intellectu
properti
discoveri
also
help
integr
gener
knowledg
public
health
system
similarli
thailand
tcel
pharmacogenom
project
virtu
associ
tcel
abil
use
avail
inhous
lawyer
manag
intellectu
properti
need
tcel
also
work
close
depart
intellectu
properti
ministri
commerc
exampl
tcel
assist
file
intellectu
properti
protect
coordin
research
extern
organ
analys
matur
innov
find
potenti
investor
licens
opportun
negoti
royalti
term
agreement
although
genotyp
project
least
mexico
thailand
seem
aspir
foster
develop
commerci
product
intellectu
properti
protect
awar
concret
product
servic
shortterm
pipelin
furthermor
product
servic
unlik
develop
soon
consid
complex
research
initi
therefor
search
evid
current
smalltomedium
enterpris
activ
develop
human
genom
medicin
product
servic
find
specif
firm
mexico
although
thailand
two
startup
compani
offer
person
genotyp
well
servic
identifi
india
avesthagen
announc
initi
largescal
genotyp
project
parsi
genom
show
evid
burgeon
local
privatesector
involv
human
genom
variat
studi
genom
medicin
despit
exist
compani
earli
develop
provid
detail
analysi
capabl
busi
model
econom
benefit
howev
key
inform
privat
sector
tell
us
interfac
public
research
centr
often
challeng
creat
maintain
bridg
public
commerci
sector
thought
necessari
knowledg
translat
commerci
despit
exist
sceptic
around
adopt
genom
medicin
emerg
market
develop
countri
exampl
indic
effort
increas
likelihood
knowledg
gener
provid
competit
edg
knowledgebas
economi
conclud
remark
human
genom
project
foundat
hous
repres
futur
genom
mexico
india
thailand
alreadi
claim
build
room
hous
glossari
admixtur
pattern
genet
variat
result
popul
deriv
founder
origin
one
ancestr
popul
dna
segment
contain
marker
signific
linkag
disequilibrium
impli
low
recombin
activ
within
block
linkag
disequilibrium
ld
measur
genet
associ
allel
differ
loci
indic
whether
allel
marker
associ
chromosom
common
expect
union
therapi
diagnost
determin
presenc
seri
predict
biomark
includ
genom
metabolom
proteom
marker
theragnost
enabl
clinician
physician
limit
number
advers
drug
reaction
refin
treatment
patient
intern
collabor
china
india
indonesia
japan
korea
malaysia
nepal
philippin
singapor
thailand
taiwan
aim
studi
genet
divers
asian
popul
result
studi
made
avail
public
although
initi
focus
health
applic
goal
uncov
breadth
genet
divers
extent
genet
similar
asia
human
genom
organ
hugo
intern
organ
scientist
origin
involv
human
genom
project
hugo
pacif
sponsor
panasian
snp
initi
chapter
hugo
base
univers
tokyo
japan
studi
began
middl
complet
late
ref
one
china
beij
genom
institut
prepar
sequenc
entir
genom
one
hundr
chines
individu
south
africa
africa
genom
educ
institut
devot
educ
public
structur
function
genom
plan
studi
genet
basi
diseas
relev
south
african
popul
brazil
long
consid
leader
genom
scienc
develop
world
invest
cancer
genom
see
genom
advanc
brazil
world
health
organ
web
site
sequenc
parasit
plant
genom
specif
organ
nucleotid
sequenc
analysi
onsa
sao
paulo
brazil
complet
first
publish
sequenc
xylella
fastidiosa
bacterium
plant
pathogen
respons
diseas
econom
import
crop
citru
effort
larg
part
respons
establish
subsequ
capac
genom
scienc
brazil
brought
moder
econom
benefit
alellyx
instanc
biotechnolog
compani
spun
onsa
network
focus
crop
econom
import
brazil
alellyx
also
hold
amongst
other
us
patent
whole
genom
gene
sequenc
diseas
diagnost
x
fastidiosa
current
use
develop
diseas
resist
pesticid
research
addit
case
studi
exampl
indic
emerg
economi
begin
establish
foothold
genom
scienc
find
report
suggest
clear
motiv
genotyp
associ
lifesci
initi
improv
health
captur
valu
research
help
creat
knowledg
economi
found
polit
institut
leadership
crucial
develop
vision
plan
implement
largescal
popul
genotyp
initi
mexico
india
thailand
contrast
mani
develop
countri
found
three
countri
focus
practic
applic
genom
rather
sole
advanc
basic
research
anoth
differ
three
develop
countri
develop
countri
extent
industri
exampl
glaxosmithklin
drive
genom
research
develop
develop
countri
also
inmegen
mexico
uniqu
extent
integr
public
health
need
partli
owe
relationship
incept
mexican
ministri
health
largescal
human
genotyp
project
describ
articl
unlik
earli
sequenc
effort
brazil
help
build
scientif
capac
line
increas
focu
innov
scienc
technolog
engin
econom
growth
develop
countri
set
scene
local
discoveri
develop
commerci
deliveri
afford
health
product
might
allow
countri
competit
global
economi
perhap
nich
area
leapfrog
ahead
advanc
economi
